Cerevel Therapeutics
Boston
About Cerevel Therapeutics
Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. Cerevel Therapeutics has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson’s disease and substance use disorder.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 10,001+
- Total funding: $1.9B
- Funding stage: M&A
- Last round: Post-IPO Equity (Oct 2023)
- Ticker: nasdaq:CERE
- Website: cerevel.com
Industries & Categories
Biotechnology, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/cerevel-therapeutics-4267 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.